Tenofovir maleateReverse transcriptase inhibitor CAS# 1236287-04-9 |
- Emtricitabine
Catalog No.:BCC3774
CAS No.:143491-57-0
- Tenofovir
Catalog No.:BCC2500
CAS No.:147127-20-6
- Entecavir Hydrate
Catalog No.:BCC1109
CAS No.:209216-23-9
- Lersivirine
Catalog No.:BCC1698
CAS No.:473921-12-9
- Didanosine
Catalog No.:BCC3763
CAS No.:69655-05-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1236287-04-9 | SDF | Download SDF |
| PubChem ID | 53302693 | Appearance | Powder |
| Formula | C13H18N5O8P | M.Wt | 403.28 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | GS 1278 maleate; PMPA maleate; TDF maleate | ||
| Solubility | Soluble in DMSO | ||
| Chemical Name | [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid;(Z)-but-2-enedioic acid | ||
| SMILES | CC(CN1C=NC2=C1N=CN=C2N)OCP(=O)(O)O.C(=CC(=O)O)C(=O)O | ||
| Standard InChIKey | OPQKUDVCYGLXAH-REVJHSINSA-N | ||
| Standard InChI | InChI=1S/C9H14N5O4P.C4H4O4/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14;5-3(6)1-2-4(7)8/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17);1-2H,(H,5,6)(H,7,8)/b;2-1-/t6-;/m1./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.In Vitro:Tenofovir shows cytotoxic effects on cell viability in HK-2 cells, with IC50 values of 9.21 and 2.77 μM at 48 and 72 h in MTT assay, respectively. Tenofovir diminishes ATP levels in HK-2 cells. Tenofovir (3.0 to 28.8 μM) increases oxidative stress and protein carbonylation in HK-2 cells. Furthermore, Tenofovir induces apoptosis in HK-2 cells, and that apoptosis is induced via mitochondrial damage[1]. Tenofovir and M48U1 formulated in 0.25% HEC each inhibits the replication of both R5-tropic HIV-1BaL and X4-tropic HIV-1IIIb in activated PBMCs, and inhibits several laboratory strains and patient-derived HIV-1 isolates. The combined formulation of M48U1 and tenofovir in 0.25% HEC exhibits synergistic antiretroviral activity against infection with R5-tropic HIV-1BaL, and is not toxic to PBMCs[2].In Vivo:Tenofovir Disoproxil Fumarate (20, 50, 140, or 300 mg/kg) administered to BLT mice, shows dose dependent activity during vaginal HIV challenge in BLT humanized mice. Tenofovir Disoproxil Fumarate (50, 140, 300 mg/kg) significantly reduces HIV transmission in BLT mice[3]. Tenofovir Disoproxil Fumarate (0.5, 1.5, or 5.0 mg/kg/day, p.o.) induces a dose-dependent decline in serum viremia in woodchucks chronically infected with WHV. Tenofovir Disoproxil Fumarate administration is safe and effective in the woodchuck model of chronic HBV infection[4]. References: | |||||
Tenofovir maleate Dilution Calculator
Tenofovir maleate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4797 mL | 12.3983 mL | 24.7967 mL | 49.5933 mL | 61.9917 mL |
| 5 mM | 0.4959 mL | 2.4797 mL | 4.9593 mL | 9.9187 mL | 12.3983 mL |
| 10 mM | 0.248 mL | 1.2398 mL | 2.4797 mL | 4.9593 mL | 6.1992 mL |
| 50 mM | 0.0496 mL | 0.248 mL | 0.4959 mL | 0.9919 mL | 1.2398 mL |
| 100 mM | 0.0248 mL | 0.124 mL | 0.248 mL | 0.4959 mL | 0.6199 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Tenofovir maleate is an inhibitor of reverse transcriptase used for the treatment of the human immunodeficiency virus 1(HIV-1) and hepatitis B [1].
Tenofovir maleate is an antiviral pro-drug and the class of nucleoside reverse transcriptase inhibitor. In addition, Tenofovir maleate has been reported to have a dependent relation between intracellular the drug concentrations and prevent function of HIV-1infection with EC50 values of 29 fmol/106, 40 fmol/106 , 77 fmol/106 and 411 fmol/106 cells for inoculum size 1, 5, 20 and 100 respectively. And the EC50 values of tenofovir maleate are 267 fmol/106, 348 fmol/106, 640 fmol/106 and 2866 fmol/106 cells for virus inoculums size 1, 5, 20 and 100, respectively [1].
References:
[1] Duwal S1, Schütte C, von Kleist M.Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. PLoS One. 2012;7(7):e40382. doi: 10.1371/journal.pone.0040382. Epub 2012 Jul 11.
- Diosbulbin L
Catalog No.:BCN7305
CAS No.:1236285-87-2
- Salviaplebeiaside
Catalog No.:BCN7304
CAS No.:1236273-88-3
- Clerosterol glucoside
Catalog No.:BCN6123
CAS No.:123621-00-1
- 740 Y-P
Catalog No.:BCC5861
CAS No.:1236188-16-1
- PHP 501 trifluoroacetate
Catalog No.:BCC6193
CAS No.:1236105-75-1
- Curcumadionol
Catalog No.:BCN3561
CAS No.:1235984-45-8
- Peptide YY(3-36), PYY, human
Catalog No.:BCC1041
CAS No.:123583-37-9
- rac BHFF
Catalog No.:BCC7644
CAS No.:123557-91-5
- AQ-RA 741
Catalog No.:BCC7314
CAS No.:123548-16-3
- Azelnidipine
Catalog No.:BCC4400
CAS No.:123524-52-7
- Linderaspirone A
Catalog No.:BCN6122
CAS No.:1235126-46-1
- Biperiden HCl
Catalog No.:BCC4565
CAS No.:1235-82-1
- Fmoc-Glu(OBzl)-OH
Catalog No.:BCC3493
CAS No.:123639-61-2
- NS 398
Catalog No.:BCC6857
CAS No.:123653-11-2
- Iguratimod
Catalog No.:BCC1641
CAS No.:123663-49-0
- Pimasertib (AS-703026)
Catalog No.:BCC2529
CAS No.:1236699-92-5
- Trigoxyphin A
Catalog No.:BCN6875
CAS No.:1236874-00-2
- Bongardol
Catalog No.:BCN6124
CAS No.:123690-76-6
- CGP 35348
Catalog No.:BCC6988
CAS No.:123690-79-9
- CGP 46381
Catalog No.:BCC6990
CAS No.:123691-14-5
- CGP 36216 hydrochloride
Catalog No.:BCC7605
CAS No.:123691-29-2
- Kuwanol C
Catalog No.:BCN3941
CAS No.:123702-94-3
- Moracin O
Catalog No.:BCN4004
CAS No.:123702-97-6
- Acetyl-Calpastatin (184-210) (human)
Catalog No.:BCC2350
CAS No.:123714-50-1
